Structure Therapeutics (GPCR) Cash & Equivalents (2022 - 2026)

Structure Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 73.6% year-over-year to $1.5 billion in Q1 2026; TTM through Mar 2026 was $1.5 billion, a 73.6% increase from a year earlier, with the FY2025 full-year figure at $799.6 million, down 8.65% from the prior year.
• Cash & Equivalents improved to $1.5 billion in Q1 2026 per GPCR's latest filing, from $799.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.5 billion in Q1 2026 and bottomed at $26.1 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $212.5 million (2023), against an average of $447.8 million.
• Biggest YoY gain for Cash & Equivalents was 755.45% in 2025; the steepest drop was 61.47% in 2025.
• Year by year, Cash & Equivalents stood at $26.1 million in 2022, then surged by 397.46% to $129.8 million in 2023, then soared by 574.41% to $875.3 million in 2024, then declined by 8.65% to $799.6 million in 2025, then soared by 81.7% to $1.5 billion in 2026.
• Per Business Quant, the three latest GPCR Cash & Equivalents figures stand at $1.5 billion (Q1 2026), $799.6 million (Q4 2025), and $799.0 million (Q3 2025).